{"id":8460,"date":"2022-05-31T23:44:56","date_gmt":"2022-05-31T21:44:56","guid":{"rendered":"http:\/\/mohnfoundation.webforslag.com\/prosjekt\/charalampos-tzoulis\/"},"modified":"2023-09-05T13:21:21","modified_gmt":"2023-09-05T11:21:21","slug":"charalampos-tzoulis","status":"publish","type":"prosjekt","link":"https:\/\/mohnfoundation.no\/en\/prosjekt\/charalampos-tzoulis\/","title":{"rendered":"Charalampos Tzoulis"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row el_class=&#8221;article-white&#8221; css=&#8221;.vc_custom_1649536549777{margin-right: 0px !important;margin-left: 0px !important;}&#8221;][vc_column][vc_row_inner][vc_column_inner]<div class=\"spacer-f96c97828f0d47b1724343c705ecae9d423\" style=\"\"><\/div><style>@media (min-width: 320px) { .spacer-f96c97828f0d47b1724343c705ecae9d423{ height: 10px;}}@media (min-width: 767px) { .spacer-f96c97828f0d47b1724343c705ecae9d423{ height: 10px;}}@media (min-width: 979px) { .spacer-f96c97828f0d47b1724343c705ecae9d423{ height: 10px;}}@media (min-width: 1200px) { .spacer-f96c97828f0d47b1724343c705ecae9d423{ height: 10px;}}<\/style><div class=\"header left  \"><h1 class=\"font-size-sm\" title=\"Charalampos Tzoulis\">Charalampos Tzoulis<\/h1><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=&#8221;3\/4&#8243;]\n                    <div class=\"info-container\">\n                        <div class=\"fields row\">  <div class=\"field1 col-lg-4 col-md-4 col-sm-12\">\n                                            <div class=\"field1-header\" >\n                                            TMS-projec\n                                            <\/div >\n                                            <div class=\"field1-number\" >\n                                            Using Multidimensional Integration of Biological Systems to Unravel the Pathogenesis of Parkinson\u2019s Disease\n                                            <\/div >\n                                        <\/div> <div class=\"field2 col-lg-4 col-md-4 col-sm-12\">\n                                            <div class=\"field2-header\" >\n                                            Period\n                                            <\/div >\n                                            <div class=\"field2-number\" >\n                                            2017 - 2021\n                                            <\/div >\n                                        <\/div> <div class=\"field3 col-lg-4 col-md-4 col-sm-12\">\n                                            <div class=\"field3-header\" >\n                                            Department\n                                            <\/div >\n                                            <div class=\"field3-number\" >\n                                            Department of Clinical Medicine\n                                            <\/div >\n                                        <\/div>\n                        <\/div>   \n                    <\/div>[vc_column_text]Charalampos Tzoulis MD, PhD, is Professor of Neurology and Neurodegeneration, Director of the Neuromics Research Group (<a href=\"https:\/\/neuromics.org\/\" target=\"_blank\" rel=\"noopener\">https:\/\/neuromics.org\/<\/a>), and Director for Neurodegeneration at the Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases (<a href=\"https:\/\/www.neuro-sysmed.no\/\" target=\"_blank\" rel=\"noopener\">www.neuro-sysmed.no<\/a>), University of Bergen and Haukeland University Hospital, Bergen, Norway.<\/p>\n<p>Clinically, he specializes in neurogenetic, movement disorders and neurodegenerative diseases. His research is dedicated to the study of brain aging and neurodegeneration, with a particular focus on Parkinson\u2019s disease. His mission and long-term vision are to elucidate biological mechanisms underlying neurodegeneration and to design tailored neuroprotective therapies preventing and\/or ameliorating the occurrence and progress of neurodegenerative disorders.<\/p>\n<p>Charalampos Tzoulis was born in Athens, Greece in 1979. He received his medical degree from Albert Szent-Gy\u00f6rgyi Medical University of Szeged, Hungary in 2003. He subsequently trained in neurology at Haukeland University Hospital in Bergen, Norway and received his PhD degree from the University of Bergen in 2010. He became full Professor of Neurology and Neurodegeneration in 2018, at the age of 38 years. Since 2019, he is the Co-Director and Director for Neurodegeneration at Neuro-SysMed, Norway\u2019s first National Center of Excellence for Clinical Research.<\/p>\n<p><strong>About the TMS project:<\/strong><\/p>\n<p>Parkinson\u2019s disease (PD) affects 1-2% of the population above the age of 65, and is a major cause of death and disability with a devastating global socioeconomic impact. In Europe alone, PD affects an estimated 1.2 million people and has a cost of \u20ac14 billion per year. Current treatments for PD are purely symptomatic and have no impact on disease progression. As a result, patients confront a future of progressive disability, early institutionalization, and premature death. Since demographic studies show that patient numbers will continue to grow, effectively doubling by 2040, our failure to make any significant impact to halt or delay disease progression means that PD is now a major challenge to health care and society.<\/p>\n<p>The overarching goal of Prof. Tzoulis\u2019 TMS project was to elucidate mechanisms underlying the pathogenesis of PD at the molecular level, and to utilize this knowledge to identify biomarkers for more precise diagnosis, and therapeutic targets. Working towards this goal, Tzoulis and his team have generated an integrated multi-omics map of the PD-brain \u2013 both in bulk-tissue and at single-cell resolution \u2013 combining genomics with epigenomics, transcriptomics, and proteomics. Using this unique database, they have explored single-layer as well as integrated multi-omic signatures of PD.<\/p>\n<p>Tzoulis and his team have discovered novel molecular pathways associated with PD and identified for the first time a molecular subtype of idiopathic PD, which will contribute towards personalized therapy. Moreover, their work has identified nicotinamide adenine dinucleotide (NAD) metabolism as a key pathway in PD and other neurodegenerative diseases, and nominated NAD-replenishment therapy as a potential neuroprotective therapy against PD, other parkinsonisms, Alzheimer&#8217;s disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. These findings have motivated multiple national and international clinical trials currently running under Prof. Tzoulis\u2019 supervision, to explore the potential of NAD-replenishment therapy against neurodegeneration.[\/vc_column_text]<div class=\"header left  \"><h2 class=\"font-size-sm\" title=\"Media\">Media<\/h2><\/div><div class=\"external-links-container light-brown\"><ul class=\"external-links\"><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.forskningsdagene.no\/arrangementer\/t-10813\" target=\"_blank\" rel=\"noopener\">Forskningsdagane - P\u00e5 labben<\/a><span class=\"date\">17.09<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/en\/med\/135805\/brain-gene-expression-profiles-parkinson%E2%80%99s-disease-biased-altered-cell-composition\" target=\"_blank\" rel=\"noopener\">UiB.no - Brain gene expression profiles in Parkinson\u2019s disease biased by altered cell composition<\/a><span class=\"date\">12.05.2020<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.alphagalileo.org\/en-gb\/Item-Display\/ItemId\/192276?returnurl=https:\/\/www.alphagalileo.org\/en-gb\/Item-Display\/ItemId\/192276\" target=\"_blank\" rel=\"noopener\">AlphaGalileo - The brain\u2019s powerhouses are damaged in Creutzfeldt-Jacob disease<\/a><span class=\"date\">7.05.2020<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/tv.nrk.no\/serie\/norge-naa\/201903\/ENRK10032019\/avspiller\" target=\"_blank\" rel=\"noopener\">Nrk.no - Norge N\u00e5<\/a><span class=\"date\">20.03.2019<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/neuromics.org\/2019\/02\/11\/future-of-health-in-norway-interview-of-prof-charalampos-tzoulis\/\" target=\"_blank\" rel=\"noopener\">neuromics.org - Future of health in Norway: Interview of professor Charalampos Tzouliz<\/a><span class=\"date\">11.02.209<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/med\/130743\/%C3%A5pnet-nytt-hjerneforskningssenter\" target=\"_blank\" rel=\"noopener\">UiB.no - \u00c5pnet nytt hjerneforskningssenter<\/a><span class=\"date\">18.10.2019<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.dagensmedisin.no\/artikler\/2019\/10\/17\/apnet-neuro-sysmed-i-bergen\/\" target=\"_blank\" rel=\"noopener\">Dagens medisin - \u00c5pnet Neuro-SysMed i Bergen<\/a><span class=\"date\">17.10.2019<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/neuromics.org\/2019\/02\/11\/future-of-health-in-norway-interview-of-prof-charalampos-tzoulis\/\" target=\"_blank\" rel=\"noopener\">NRK Norge i dag - Korleis er morgendagen i helsevesenet? Interview of Prof. Charalampos Tzoulis (ca 2 minutt ut i sendingen)<\/a><span class=\"date\">12. 12.2018<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/parkinson.no\/aktuelt\/nytt-forskningssenter-i-hordaland\" target=\"_blank\" rel=\"noopener\">Norsk Parkinsonforbund - Nytt forskningssenter<\/a><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/med\/121799\/160-millioner-kroner-til-nytt-senter-hjernesykdommer\" target=\"_blank\" rel=\"noopener\">UiB.no - 160-millioner-kroner-til-nytt-senter-hjernesykdommer<\/a><span class=\"date\">13.11.2018<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/med\/118482\/hedret-v%C3%A5re-beste-p%C3%A5-fakultetets-dag\" target=\"_blank\" rel=\"noopener\">UiB.no - Hedret v\u00e5re beste p\u00e5 Fakultetets dag<\/a><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/helse-bergen.no\/fag-og-forsking\/forsking\/vil-revolusjonere-behandlingen-av-parkinsons-sykdom\" target=\"_blank\" rel=\"noopener\">Helse Bergen - Vil revolusjonere behandlingen av Parkinsons sykdom<\/a><span class=\"date\">8.6.2018<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/med\/113793\/skade-i-hjernens-kraftstasjon-gunstig-ved-parkinsons-sykdom\" target=\"_blank\" rel=\"noopener\">UiB.no - Skade i hjernens kraftstasjon gunstig ved Parkinsons sykdom<\/a><span class=\"date\">5.1.2018<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.eurekalert.org\/pub_releases\/2018-01\/tuob-psi011518.php\" target=\"_blank\" rel=\"noopener\">EurekAlert.org - Power stations in cells may protect brain against Parkinson\u2019s<\/a><span class=\"date\">15.01.2018<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/node\/102720\" target=\"_blank\" rel=\"noopener\">UiB.no - \u201cPowerhouse\u201d-failure may cause Parkinson disease<\/a><span class=\"date\">10.11.2017<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.sciencedaily.com\/releases\/2017\/09\/170925111619.htm\" target=\"_blank\" rel=\"noopener\">ScienceDaily.com - Diabetes medicine reduces Parkinson\u2019s risk<\/a><span class=\"date\">25.09.2017<\/span><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/node\/110489\" target=\"_blank\" rel=\"noopener\">UiB.no - Diabetes medicine reduces Parkinson\u2019s risk<\/a><span class=\"date\">12.09.2017<\/span><\/li><\/ul><\/div>[\/vc_column_inner][vc_column_inner width=&#8221;1\/4&#8243;]\n\t\t\t<figure class=\"standard-image left no-caption\">\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"534\" height=\"349\" src=\"https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Charalampos-Tzoulis-1-e1497967892589.jpg\" class=\"attachment-img-xxl size-img-xxl\" alt=\"\" srcset=\"https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Charalampos-Tzoulis-1-e1497967892589.jpg 534w, https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Charalampos-Tzoulis-1-e1497967892589-300x196.jpg 300w, https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Charalampos-Tzoulis-1-e1497967892589-320x209.jpg 320w, https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Charalampos-Tzoulis-1-e1497967892589-420x274.jpg 420w\" sizes=\"auto, (max-width: 534px) 100vw, 534px\" \/>\n\t\t\t\t\n\t\t\t<\/figure><div class=\"external-links-container blue-arrow-right\"><ul class=\"external-links\"><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.uib.no\/personer\/Charalampos.Tzoulis\" target=\"_blank\" rel=\"noopener\">Homepage at the University of Bergen<\/a><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/neuromics.org\/\" target=\"_blank\" rel=\"noopener\">Project website<\/a><\/li><li class=\"inner-item\"><i class=\"fa fa-external-link\"><\/i><a href=\"https:\/\/www.cristin.no\/as\/WebObjects\/cristin.woa\/wa\/personVis?type=PERSON&amp;pnr=44838&amp;la=no&amp;instnr=1936\" target=\"_blank\" rel=\"noopener\">Publications registered in CRIStin<\/a><\/li><\/ul><\/div>[\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]<div class=\"spacer-f4de40bb4e7b53dd110c90e1adcadb9a23\" style=\"\"><\/div><style>@media (min-width: 320px) { .spacer-f4de40bb4e7b53dd110c90e1adcadb9a23{ height: 30px;}}@media (min-width: 767px) { .spacer-f4de40bb4e7b53dd110c90e1adcadb9a23{ height: 30px;}}@media (min-width: 979px) { .spacer-f4de40bb4e7b53dd110c90e1adcadb9a23{ height: 60px;}}@media (min-width: 1200px) { .spacer-f4de40bb4e7b53dd110c90e1adcadb9a23{ height: 60px;}}<\/style>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Charalampos Tzoulis MD, PhD, er nevrolog ved Haukeland Universitetssjukehus og leder av forskningsgruppen:  Translational Science in Neurodegeneration and Aging (TSNA) ved Universitetet i Bergen. Oppstart 2017. [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary vidiflex-read-more-link\" href=\"https:\/\/mohnfoundation.no\/en\/prosjekt\/charalampos-tzoulis\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"featured_media":5230,"template":"","categories":[39],"class_list":["post-8460","prosjekt","type-prosjekt","status-publish","has-post-thumbnail","hentry","category-projects"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/prosjekt\/8460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/prosjekt"}],"about":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/types\/prosjekt"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/media\/5230"}],"wp:attachment":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/media?parent=8460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/categories?post=8460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}